Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPID: Nab-Rapamycin in Advanced Cancers
NCT02646319Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Jan 2016
- Primary completion
- Sep 2017
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nab-sirolimus in cancer, sponsored by Mayo Clinic. Primary endpoint: Objective Response Rate at 21 days. Started Jan 2016; status: completed.
02
Drugs
nab-sirolimus
03
Conditions
cancer
Beyond the preview
Go deeper on NCT02646319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02646319.